Skip to main content

Human IGFBP-4 Antibody

R&D Systems, part of Bio-Techne | Catalog # MAB8041

R&D Systems, part of Bio-Techne
Catalog #
Availability
Size / Price
Qty
Loading...
MAB8041
MAB8041-SP

Key Product Details

Species Reactivity

Validated:

Human

Cited:

Human

Applications

Validated:

ELISA Capture (Matched Antibody Pair), Neutralization, Western Blot

Cited:

ELISA Development

Label

Unconjugated

Antibody Source

Monoclonal Mouse IgG1 Clone # 82314

Product Specifications

Immunogen

Mouse myeloma cell line NS0-derived recombinant human IGFBP-4
Asp22-Glu258
Accession # AAA62670

Specificity

Detects human IGFBP-4 in ELISAs and Western blots.

Clonality

Monoclonal

Host

Mouse

Isotype

IgG1

Endotoxin Level

<0.10 EU per 1 μg of the antibody by the LAL method.

Scientific Data Images for Human IGFBP-4 Antibody

IGFBP-4 Inhibition of IGF-II-dependent Cell Proliferation and Neutralization by Human IGFBP-4 Antibody.

IGFBP-4 Inhibition of IGF-II-dependent Cell Proliferation and Neutralization by Human IGFBP-4 Antibody.

Recombinant Human IGFBP-4 (Catalog # 804-GB) inhibits Recombinant Human IGF-II (Catalog # 292-G2) induced proliferation in the MCF-7 human breast cancer cell line in a dose-dependent manner (orange line). Inhibition of Recombinant Human IGF-II (14 ng/mL) activity elicited by Recombinant Human IGFBP-4 (0.3 µg/mL) is neutralized (green line) by increasing concentrations of Mouse Anti-Human IGFBP-4 Monoclonal Antibody (Catalog # MAB8041). The ND50 is typically 20-80 µg/mL.

Applications for Human IGFBP-4 Antibody

Application
Recommended Usage

Western Blot

1 µg/mL
Sample: Recombinant Human IGFBP-4 (Catalog # 804-GB)

Neutralization

Measured by its ability to neutralize IGFBP‑4 inhibition of IGF‑II-dependent proliferation in the MCF‑7 human breast cancer cell line. Karey, K. P. et al. (1988) Cancer Research 48:4083. The Neutralization Dose (ND50) is typically 20‑80 µg/mL in the presence of 0.3 µg/mL Recombinant Human IGFBP‑4 and 14 ng/mL Recombinant Human IGF‑II.

Human IGFBP-4 Sandwich Immunoassay

ELISA Capture (Matched Antibody Pair)
Recommended Concentration: 2-8 µg/mL
Use in combination with these reagents:
  • Detection Reagent: Human IGFBP-4 Biotinylated Antibody (Catalog # BAF804)
  • Standard: Recombinant Human IGFBP-4 Protein, CF (Catalog # 804-GB)
Please Note: Optimal dilutions of this antibody should be experimentally determined.

Formulation, Preparation, and Storage

Purification

Protein A or G purified from ascites

Reconstitution

Reconstitute at 0.5 mg/mL in sterile PBS. For liquid material, refer to CoA for concentration.

Reconstitution Buffer Available:
Size / Price
Qty
Loading...

Formulation

Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied either lyophilized or as a 0.2 µm filtered solution in PBS.

Shipping

Lyophilized product is shipped at ambient temperature. Liquid small pack size (-SP) is shipped with polar packs. Upon receipt, store immediately at the temperature recommended below.

Stability & Storage

Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 6 months, -20 to -70 °C under sterile conditions after reconstitution.

Background: IGFBP-4

Human IGF binding protein 4 (IGFBP-4) was isolated from human plasma based on its ability to bind immobilized IGF-I. Human IGFBP-4 cDNA encodes a 258 amino acid (aa) residue precursor protein with a predicted 21 aa residue signal peptide that is processed to generate the 237 aa residue mature human IGFBP-4. The human IGFBP-4 contains a potential N-linked glycosylation site and shares approximately 90% amino acid sequence identity with both the mouse and rat IGFBP-4. According to the nomenclature of IGFBPs defined at the 4th International Symposium of IGFs (1997, Tokyo), six high-affinity IGF binding proteins (IGFBP-1, -2, -3, 4, -5, -6), and four IGFBP-related proteins (IGFBPr-1, - 2, -3, -4) have been identified. All IGFBPs have a high cysteine content and share conserved cysteine residues that are clustered in the amino- and carboxy-terminal third of the molecule. IGFBPs have been shown to either inhibit or enhance the biological activities of IGF, or act in an IGF-independent manner. Post-translational modification of IGFBPs, including phosphorylation and proteolysis, have been shown to modify the affinities of the binding proteins for IGF and may indirectly regulate IGF actions.

References

  1. Jones, J.I. and D.R. Clemons (1995) Endocrine Rev. 16:3.
  2. Kelly, K.M. et al. (1996) Intl. J. Biochem. Cell Biol. 28:619.
  3. Kim, H-S. et al. (1997) Proc. Natl. Acad. Sci. USA 94:12981.

Long Name

Insulin-like Growth Factor Binding Protein 4

Alternate Names

IGFBP4

Entrez Gene IDs

3487 (Human); 16010 (Mouse)

Gene Symbol

IGFBP4

UniProt

Additional IGFBP-4 Products

Product Documents for Human IGFBP-4 Antibody

Certificate of Analysis

To download a Certificate of Analysis, please enter a lot number in the search box below.

Note: Certificate of Analysis not available for kit components.

Product Specific Notices for Human IGFBP-4 Antibody

For research use only

Loading...
Loading...
Loading...
Loading...